Aurobindo Pharma (BOM:524804) Beta: 0.7548 (As of Jun. 29, 2026)


BOM:524804 Aurobindo Pharma Ltd BOM:524804
85 GF Score
Price ₹1,554.95
GF Value ₹1,322.24
Valuation Modestly Overvalued
! 7 Warning Signs
View Full Analysis

What is Aurobindo Pharma Beta?

Aurobindo Pharma BOM:524804 +1.65% 85 Beta is 0.7548 as of Jun. 29, 2026. GuruFocus rates BOM:524804 with a GF Score™ of 85/100 and a GF Value™ of ₹1,322.24 (Modestly Overvalued). The stock has 7 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-29), Aurobindo Pharma's Beta is 0.7548.


Aurobindo Pharma  (BOM:524804) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Aurobindo Pharma Beta Related Terms


Aurobindo Pharma Beta Historical Data

* Premium members only.

The historical data trend for Aurobindo Pharma's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aurobindo Pharma Beta Chart

Aurobindo Pharma Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.81 1.02 0.62 1.26 0.88

Aurobindo Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.26 1.12 1.23 1.40 0.88

BOM:524804 vs ZTS, UTHR: Beta Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Aurobindo Pharma's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aurobindo Pharma Beta vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Aurobindo Pharma's Beta distribution charts can be found below:

* The bar in red indicates where Aurobindo Pharma's Beta falls into.


BOM:524804
85GF Score
Aurobindo Pharma Ltd BOM:524804
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aurobindo Pharma Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 0.7548 mean?
Aurobindo Pharma (BOM:524804) has a Beta of 0.7548 as of Jun. 29, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Aurobindo Pharma and its competitors.
Is Aurobindo Pharma's Beta too high?
Aurobindo Pharma's current Beta is 0.7548. Overall, Aurobindo Pharma has a GF Score™ of 85/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Aurobindo Pharma's Beta compare to ZTS and UTHR?
Aurobindo Pharma's Beta of 0.7548 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Drug Manufacturers company?
A good Beta depends on the Drug Manufacturers industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Aurobindo Pharma and its competitors. Aurobindo Pharma's current Beta is 0.7548. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aurobindo Pharma stock overvalued right now?
Based on GuruFocus' analysis, Aurobindo Pharma (BOM:524804) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹1,322.24, compared to a current price of ₹1,554.95 — trading 17.6% above its estimated fair value. The current Beta is 0.7548. Aurobindo Pharma's overall GF Score™ is 85/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Aurobindo Pharma (BOM:524804), the current Beta is 0.7548 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Aurobindo Pharma (BOM:524804) Overvalued in 2026?

Based on GuruFocus' analysis, Aurobindo Pharma stock appears to be overvalued. The current stock price of ₹1,554.95 is trading 17.6% above its estimated GF Value™ of ₹1,322.24. GuruFocus considers Aurobindo Pharma to be Modestly Overvalued.

Key valuation signals for BOM:524804:

  • Beta: 0.7548
  • GF Value™: ₹1,322.24 vs. price of ₹1,554.95 (17.6% above fair value)
  • GF Score™: 85/100 with 7 warning signs

No single metric tells the full story. See the BOM:524804 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Aurobindo Pharma Business Description

Other Exchanges AUROPHARMA:India
Address Plot No. 1, Survey No. 83/1, Galaxy, Floors 22-24, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad, TG, IND, 500032
Aurobindo Pharma Ltd is a specialty and generic drug manufacturing company. It is principally engaged in the manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals, and related services. Its formulations target key therapeutic areas, including Central Nervous System (CNS), Antibiotics, Anti-diabetics, Cardiovascular, Anti-retroviral, Gastroenterology, Oncology, and Dermatology. The operating and reportable segments of the company are; India, the United States of America, Europe, and the Rest of the World. The company generates a majority of its revenue from its business in the United States of America.
85GF Score

Get the complete analysis for BOM:524804

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,554.95
Price
₹1,322.24
GF Value